Literature DB >> 10679505

Role of alpha(2)-adrenergic receptor subtypes in the acute hypertensive response to hypertonic saline infusion in anephric mice.

K P Makaritsis1, C Johns, I Gavras, H Gavras.   

Abstract

Experimental evidence suggests that the acute hypertensive response induced in anephric animals by infusion of a hypertonic saline solution is mediated by disinhibition of the presynaptic sympathoinhibitory alpha(2)-adrenergic receptors (alpha(2)-AR) of the central nervous system. The purpose of the present experiments was to dissect the role of the 3 distinct alpha(2)-AR subtypes (alpha(2A)-, alpha(2B), - and alpha(2C)-AR) in this response. Groups of genetically engineered mice deficient in each one of these alpha(2)-AR subtype genes were submitted to bilateral nephrectomy followed by a 0.4-mL infusion of 4% saline over a 2-hour period, with constant direct blood pressure (BP) monitoring. The alpha(2A)-AR-deficient and alpha(2C)-AR-deficient mice responded with significant BP elevations (by 11.8+/-2.5 and 16.7+/-1.7 mm Hg, respectively), and so did their wild-type counterparts (17.8+/-2.5 and 11.8+/-2.0 mm Hg, respectively) and the wild-type alpha(2B) +/+ (13.1+/-2.4 mm Hg). However, the alpha(2B)-AR-deficient mice were unable to raise their BP and had a slightly lowered BP (by -3.0+/-4. 0 mm Hg) at the end of the infusion period. All 6 groups exhibited elevated plasma norepinephrine levels ranging between 0.8 and 1.8 ng/mL at the end of the infusion. In all cases, the alpha(2)-AR-deficient groups tended to have higher norepinephrine levels than their wild-type counterparts. Surprisingly, this difference was significant only in the alpha(2B)-AR-deficient mice, which, despite the elevated norepinephrine, were unable to raise their BP. The data suggest that a full complement of the alpha(2B)-AR is needed to mediate the hypertensive response to acute saline load, even though its absence does not prevent the release of norepinephrine under these conditions.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10679505     DOI: 10.1161/01.hyp.35.2.609

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  6 in total

1.  Inhibition of the alpha(1D)-adrenergic receptor gene by RNA interference (RNAi) in rat vascular smooth muscle cells and its effects on other adrenergic receptors.

Authors:  Bei Sun; Ekaterina Kintsurashvili; Deborah Ona; Ivana Ignjacev-Lazich; Irene Gavras; Haralambos Gavras
Journal:  Vascul Pharmacol       Date:  2007-01-23       Impact factor: 5.773

Review 2.  Mouse models of blood pressure regulation and hypertension.

Authors:  F Sugiyama; K Yagami ; B Paigen
Journal:  Curr Hypertens Rep       Date:  2001-02       Impact factor: 5.369

3.  Subcellular distribution of α2-adrenoceptor subtypes in the rodent kidney.

Authors:  Takaomi Shimokawa; Toshitaka Nakagawa; Kohei Hayashi; Masayo Yamagata; Kozo Yoneda
Journal:  Cell Tissue Res       Date:  2021-11-27       Impact factor: 5.249

4.  Recombinant Adeno-Associated Virus-Mediated Delivery of MicroRNA-21-3p Lowers Hypertension.

Authors:  Feng Wang; Qin Fang; Chen Chen; Ling Zhou; Huaping Li; Zhongwei Yin; Yan Wang; Chun Xia Zhao; Xiao Xiao; Dao Wen Wang
Journal:  Mol Ther Nucleic Acids       Date:  2017-11-24       Impact factor: 8.886

5.  The insertion/deletion variation in the alpha2B-adrenoceptor does not seem to modify the risk for acute myocardial infarction, but may modify the risk for hypertension in sib-pairs from families with type 2 diabetes.

Authors:  Amir Snapir; Mika Scheinin; Leif C Groop; Marju Orho-Melander
Journal:  Cardiovasc Diabetol       Date:  2003-11-24       Impact factor: 9.951

6.  Long-term exposure to concentrated ambient PM2.5 increases mouse blood pressure through abnormal activation of the sympathetic nervous system: a role for hypothalamic inflammation.

Authors:  Zhekang Ying; Xiaohua Xu; Yuntao Bai; Jixin Zhong; Minjie Chen; Yijia Liang; Jinzhuo Zhao; Dongyao Liu; Masako Morishita; Qinghua Sun; Catherine Spino; Robert D Brook; Jack R Harkema; Sanjay Rajagopalan
Journal:  Environ Health Perspect       Date:  2013-11-15       Impact factor: 9.031

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.